Vitekta (elvitegravir)

17:17 EST 22nd November 2017 | BioPortfolio

Gilead Sciences’ Vitekta (elvitegravir), an oral HIV integrase inhibitor for use as part of HIV treatment regimens that include a ritonavir-boosted protease inhibitor, has gained approval in the EU and Australia. Viteka, like Isentress (raltegravir), inhibits HIV integrase, preventing integration of viral DNA into host DNA. The compound is suitable for once-daily dosing and has a lower potential to cause liver damage compared to Isentress.

A marketing authorization application was approved in the EU under the centralized procedure in November 2013.

Vitekta™ (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir. Vitekta is indicated for use as part of HIV treatment regimens that include a ritonavir-boosted protease inhibitor. Vitekta interferes with HIV replication by blocking the virus from integrating into the genetic material of human cells. In clinical trials, Vitekta was effective in suppressing HIV among patients with drug-resistant strains of HIV. - See more at:


Quick Search

review and buy Vitekta (elvitegravir) market research data and corporate reports here